Leading up to #RareDiseaseDay, we’re talking about the importance of #newbornscreening for rare genetic diseases. We support the inclusion of Duchenne in existing #NBS programs so that that all patients have the chance to benefit from early diagnosis and treatment.

We just announced our Q4 and full-year 2023 financial results and recent corporate developments.

Today, we announced the opening of Route 79, The Duchenne Scholarship Program. Created to help those affected by #Duchenne pursue their post-high-school educational goals, the program will award 25 scholarships. Read the press release to learn more: bit.ly/3ThgyFA

Today, we announced the opening of the 2024 Sarepta LGMD Grant Award Program. Open to non-governmental and patient advocacy organizations from across the globe, it aims to help shorten the LGMD diagnostic journey. Read our news release to learn more: bit.ly/3PsPCQK

Congratulations to Dr. Jerry Mendell on being named to the inaugural Time100 Health list! The list recognizes individuals who most influenced global health this year, and it is an acknowledgement of Dr. Mendell’s impact, innovation and achievement.

Are you heading to #ASGCT2024 in Baltimore? Come find our Sarepta team! We are excited to be among peers dedicated to gene and cell therapy.

We’re thrilled to be a Diamond sponsor CureDuchenne’s FUTURES conference on May 23-26 and look forward to connecting with families in Orlando, Florida.

Are you attending CureDuchenne FUTURES and have a question for Sarepta? Our team is available throughout the conference at our two booths and our Lego activity. Hope to see you there!

On Juneteenth, well-deserved recognition of 18 influential Black leaders in biopharma, including Sarepta EVP and CFO, Ian Estepan. timmermanreport.com/2024/06/on-jun…

Today we announced an important development regarding FDA approval of our gene therapy. Watch to hear a message from our CEO, Doug Ingram:

Our head of R&D and Chief Scientific Officer, Louise Rodino-Klapac, PhD, on today’s news regarding advances in the treatment of Duchenne muscular dystrophy:

We are the leaders in providing treatment options for the Duchenne community, and we remain steadfastly committed to furthering progress for every person living with Duchenne. We’re proud to be a Star sponsor of Parent Project Muscular Dystrophy (PPMD)’s Annual Conference this year.

Today is the last day to apply for our 2024 LGMD grant program, an initiative that awards funds to organizations that can help drive LGMD awareness and education. Apply here: Sarepta.com/LGMDGrantAward…

On our #Q2Results call, CEO Doug Ingram discussed our second-quarter performance and shared an update on recent corporate developments, including the label expansion for our Duchenne therapy.

Important progress in #NewbornScreening in Massachusetts: Duchenne was added to the state’s newborn screening panel as part of maternal health plan. We applaud Mass leadership and urge federal leaders to follow suit & add screening for Duchenne nationwide. bit.ly/4fZvG3E

September is #NewbornScreeningAwarenessMonth! Learn about the progress in expanding newborn screening to include Duchenne. It’s a crucial step to eliminate diagnostic delays. We applaud efforts to expand screening in more states. #Duchenne #NBS

Congratulations to the recipients of the 2024 Route 79 Scholarships! This program provides academic scholarships to those living with #Duchenne and siblings in Duchenne families to support post-secondary educational goals. Read the press release: bit.ly/3Z8pwZd

Today is World Duchenne Awareness Day, a day dedicated to raising global awareness of #Duchenne muscular dystrophy. Like we do each year on this day, we’re wearing wear red to show support for individuals and families impacted by this rare genetic disease. #WDAD2024

We’re lighting up red for Duchenne! Our Cambridge HQ is glowing with red lights for World Duchenne Awareness Day. We’re proud to light up the block and show our support for the Duchenne community. #WDAD2024 #LightingUpForDuchenne